CADET BRAF Mutation Test
BRAF mutation test is a diagnostic molecular biomarker of canine transitional cell carcinoma (TCC) and prostate gland carcinoma (PC)1. Although, the gold standard way for the diagnosis of UC and PC is cytology or histopathological evaluation of the tissue usually through a biopsy. But, obtaining a biopsy sample is always challenging and risky because of its invasive nature and potential seeding of tumour cells. Often, the cytological and histopathological findings can be inconclusive due to the marked pleomorphism and masking of the tumour cells by severe inflammatory cells and artifacts. The aggressiveness of these tumors result from delayed diagnosis and therapeutic intervention. BRAF mutation testing is a highly specific method (100%) for the detection of TCC and PC3,4. Research showed that the mutation was detected in 85% of confirmed cases of canine TCC. Thus, BRAF mutation test provides a non-invasive detection of TCC and PC. The test mutation is not suitable for the diagnosis of TCC in cats.
Test Code
1001
Section
Cancer Diagnostics
Species
Canine
Specimen
Urine
Sample Container
Specific urine collection container
Turnaround time
Contact Vettto team
Packaging Instructions
Label the samples with animal name and unique identifiers using a permanent marker or adhesive label.
Please fill the animal information and history on the submittal form.
Collection Guidelines
40 ml of only free catch urine is to be collected and transfer immediately in the specific urine container having preservatives.
The urine sample can be collected over 3 days.
The urine sample is stable at room temperature for several days and does not require refrigeration.
Note : For the specific urine container or further assistance, please contact the Vettto team.
References
Mochizuki, H.; Shapiro, S.G.; Breen, M. Detection of BRAF Mutation in Urine DNA as a Molecular Diagnostic for Canine Urothelial and Prostatic Carcinoma. PLoS ONE 2015, 10, e0144170.
Mochizuki H, Kennedy K, Shapiro SG, Breen M. BRAF Mutations in Canine Cancers. PLoS One. 2015 Jun 8;10(6):e0129534
Aupperle-Lellbach, H., Kehl, A., de Brot, S. and van der Weyden, L., 2024. Clinical Use of Molecular Biomarkers in Canine and Feline Oncology: Current and Future. Veterinary sciences, 11(5), p.199.
Grassinger, J.M., Merz, S., Aupperle-Lellbach, H., Erhard, H. and Klopfleisch, R., 2019. Correlation of BRAF variant V595E, breed, histological grade and cyclooxygenase-2 expression in canine transitional cell carcinomas. Veterinary sciences, 6(1), p.31.